Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection.
| Autor: | Villanueva F; Internal Medicine, University of Florida, Gainesville, USA., Yuan C; Oncology, University of Florida, Gainesville, USA., Drane W; Radiology, University of Florida, Gainesville, USA., Dang L; Oncology, Ochsner Health System, Baton Rouge, USA., Nguyen TC; Internal Medicine, Moffitt Cancer Center, Tampa, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2020 Jan 15; Vol. 12 (1), pp. e6670. Date of Electronic Publication: 2020 Jan 15. |
| DOI: | 10.7759/cureus.6670 |
| Abstrakt: | Programmed cell death protein-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors induce tumor response by activating the patient's own immune system to fight cancer. Tumors with high tumor mutational burden or those that express high levels of PD-1/PD-L1 are more responsive to PD1/PDL1 inhibitors. There is much interest in determining how to improve response to PD-1/PD-L1 inhibitors. We report a case of a patient with metastatic bladder cancer who was primarily resistant to treatment with PD-1/PD-L1 inhibitors, then had a complete response after developing cytomegalovirus infection. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2020, Villanueva et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|